Limb-Girdle Muscular Dystrophy Type 1 – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Limb-Girdle Muscular Dystrophy Type 1 (LGMD1A, LGMD1B, LGMD1C, & Others (LGMD1D-H)) includes forms of the disorder that have an inheritance pattern called autosomal dominant. Majorly the LGMD1B comprises more than 65% of the total Limb-girdle muscular dystrophy type 1, followed by LGMD1C, LGMD1A, & Others type. The autosomal dominant forms of LGMD are less common than the autosomal recessive forms and appear later in life. In many cases, autosomal dominant LGMD progresses more slowly than autosomal recessive LGMD and has variable symptoms, even among members of the same family. Each gene mutation can cause a wide range of symptoms. LGMD1A can appear at any age, from adolescence to adulthood. This type of LGMD is distinguished by proximal muscle weakness, which is sometimes accompanied by slurred speech (dysarthria) and an abnormally tight Achilles tendon. LGMD1B causes proximal muscle weakness that gradually worsens. Affected individuals may also experience calf muscle hypertrophy and mild elbow or Achilles tendon contractures. LGMD1C is characterized by cramping muscle pain after exercise, mild to moderate proximal muscle weakness, and overgrowth of the calf muscle. LGMD1D-H short form is characterized by progressive muscle weakness that affects the hip-girdle area before spreading to the limb-girdle area.

 

The incidence of Limb-girdle muscular dystrophy type 1 varies from 3 to 4 cases per million in the USA.

 

The competitive landscape of Limb-Girdle Muscular Dystrophy Type 1 includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Limb-Girdle Muscular Dystrophy Type 1 across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Limb-Girdle Muscular Dystrophy Type 1 Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Limb-Girdle Muscular Dystrophy Type 1 – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ATYR1940        aTyr Pharma, Inc.         Phase 2

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more